ClinicalTrials.gg
RecruitingNCT06112314PRISM-MEL-301Updated Feb 25, 2026

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

A Phase 3 interventional study of Brenetafusp and Nivolumab in Advanced Melanoma, sponsored by Immunocore Ltd. Recruiting at 211 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Immunocore Ltd · Phase 3, Interventional, and Treatment

How we know · 9 judgments

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
680
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,050 studies in Melanoma with a site in United States — 242 open to participants now, 437 under way, 32 of them phase 3. Melanoma · United States.

Planned enrollment
63rd of 1,750
680 · median 37
Started
2024
with 69 others
Phase 3
107 of 2,050
10 open now
Primary completion
2027-10
later than 246 of 432 live
Registered
1,866th of 2,050
by date

Among the 2,050 studies in Melanoma with a site in United States, this one is the 63rd largest by planned enrollment of the 1,750 interventional ones that give a count, is one of 70 that started in 2024, is one of 107 in phase 3, reaches primary completion later than 246 of the 432 other live ones, and was the 1,866th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

242 of the 2,050 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

237 more — sign in →

All 242 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,050 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma.

03

Conditions studied

  • Advanced Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be HLA-A*02:01-positive
  • Participants must have confirmed Stage IV or unresectable Stage III melanoma
  • Archived or fresh tumor tissue sample that must be confirmed as adequate
  • Participants must have per 1.1
  • Participant must have BRAF V600 mutation status determined
  • Participants must have an (ECOG) performance status score of 0 or 1
  • Male and female participants of who are sexually active with a non-sterilized partner must agree to use highly effective methods of from the study screening date until 5 months after the final dose of study intervention

Exclusion criteria

Exclusion Criteria:

  • Participants with a history of a malignant disease other than those being treated in this study
  • Participants with untreated, active, or symptomatic central nervous system (CNS) or carcinomatous meningitis
  • to IMC-F106C, nivolumab, relatlimab, or any associated
  • Participants with pulmonary disease or impaired lung function
  • Participants with clinically significant cardiac disease or impaired cardiac function
  • Participants with active disease requiring treatment
  • Participants with any medical condition that is poorly controlled or that would, in the Investigator's or Sponsor's judgment, adversely impact the participant's participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results
  • Participants who received prior systemic anticancer therapy for unresectable or metastatic melanoma
  • Participants with a history of a life-threatening AE related to prior anti-PD-(L)1 or anti-LAG-3
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
680 participants (estimated)

Study arms

  • Experimental
    Arm A: Brenetafusp Low Dose + Nivolumab

    Participants receive brenetafusp Low Dose once weekly (QW) for the first 13 weeks, then every 2 weeks (Q2W) through Week 51, and then every 4 weeks (Q4W). Nivolumab is given Q4W. Closed to randomization after dose recommendation by the IDMC in November 2025.

    Drug: Brenetafusp · Drug: Nivolumab

  • Experimental
    Arm B: Brenetafusp High Dose + Nivolumab

    Participants receive brenetafusp High Dose once weekly (QW) for the first 13 weeks, then every 2 weeks (Q2W) through Week 51, and then every 4 weeks (Q4W). Nivolumab is given Q4W. Selected as go-forward experimental arm after dose recommendation by the IDMC in November 2025

    Drug: Brenetafusp · Drug: Nivolumab

  • Active comparator
    Arm C: Nivolumab OR Nivolumab + Relatlimab

    Participants receive nivolumab 480 mg monotherapy, or nivolumab 480 mg + relatlimab 160 mg, Q4W.

    Drug: Nivolumab · Drug: Nivolumab + Relatlimab

Interventions

  • Soluble PRAME-specific T cell receptor with anti-CD3 scFV concentrate for solution for intravenous (IV) infusion at a unit dose of 0.2 mg/mL.

    Also known as: IMC-F106C

  • Concentrate for solution for infusion at a unit dose of 10 mg/mL.

    Also known as: OPDIVO

  • DrugNivolumab + Relatlimab

    Drug pages: NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · RelatlimabStudies of RelatlimabRelatlimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Concentrate for solution for infusion at a unit dose of 16 mg/mL.

    Also known as: OPDUALAG

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS as assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumours (RECIST 1.1).

    Time frame: Up to ~45 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is the time from randomization to time of death from any cause.

    Time frame: Up to ~57 months

  2. Overall Response Rate (ORR)

    ORR as assessed by BICR according to RECIST 1.1.

    Time frame: Up to ~45 months

  3. Number of Participants Experiencing ≥1 Adverse Event (AE)

    An AE is defined as the appearance of (or worsening of any pre-existing) undesirable sign, symptom, or medical condition that occur in the study.

    Time frame: Up to ~57 months

  4. Number of Participants Experiencing ≥1 Serious Adverse Event (SAE)

    An SAE is any untoward medical consequence that results in death; requires inpatient hospitalization or prolongs existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or any other important medical event in the opinion of the Investigator.

    Time frame: Up to ~57 months

  5. Number of Participants Experiencing a Dose Interruption, Reduction, or Discontinuation

    The number of participants with a dose interruption, reduction, or discontinuation due to AE will be reported.

    Time frame: Up to ~45 months

  6. Maximum Plasma Concentration (Cmax) of IMC-F106C

    The Cmax of IMC-F106C will be reported.

    Time frame: Day 1 of Weeks 1, 2, and 3: Predose and 0.5 and 4 hours postdose

  7. Incidence of anti-IMC-F106C Antibodies

    The incidence of anti-IMC-F106C antibodies, including neutralizing antibodies, will be reported.

    Time frame: Up to ~45 months

  8. Association between PFS and Intra-Tumor Immune Cells

    The potential association between the effect of IMC-F106C on efficacy and intra-tumor environment will be explored. Intra-tumor environment is estimated as the ratio of CD3+ to CD163+ cells and the correlation with PFS will be estimated by the hazard ratio (+/- 95% CI) from a Cox model. This analysis will be restricted to subjects randomized to receive IMC-F106C.

    Time frame: Up to ~45 months

  9. Health-Related Quality of Life

    The change from baseline over time and between treatments of health-related quality of life will be reported.

    Time frame: Up to ~45 months

07

Study locations

201 of 211 sites recruiting

Showing the first 100 of 211 sites across 26 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Oct 2027, 40 months after the start.

Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's planned 40 months is close to that.

Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2023
First posted
Nov 1, 2023
StartActual
Jun 5, 2024
Primary completionEst.
Oct 16, 2027
CompletionEst.
Oct 16, 2027
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06112314
Lead sponsor
Immunocore Ltd
Responsible party
Sponsor
First posted
Nov 1, 2023
Start date
Jun 5, 2024
Primary completion
Oct 16, 2027 (estimated)
Completion
Oct 16, 2027 (estimated)
Last update
Feb 25, 2026

Study contacts

Immunocore Medical Information
Contact
medical.information@immunocore.com
844-466-8661
Immunocore Medical Information EU
Contact
medinfo.eu@immunocore.com
+00 800-744-51111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brenetafusp

Start the discussion